SALT LAKE CITY & SAN FRANCISCO--(BUSINESS WIRE)--TikkunLev Therapeutics, a biotechnology company developing precision therapies targeting the causal disease biology of failing heart muscle, today ...

According to the American College of Cardiology, nearly 6.7 million Americans have heart failure, more than half with preserved ejection fraction. This condition often leads to frequent ...

WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies ...

Sacubitril/valsartan does not change cognitive function, compared with valsartan, in patients with heart failure and mildly reduced or preserved ejection fraction, according to late breaking research ...

A type of cell that plays a crucial role in tissue repair after a heart attack may also inadvertently be why cutting-edge cell therapies cause an increased risk of rhythm disorders, according to a new ...